Literature DB >> 29341155

Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations.

A Machens1, M Elwerr1, K Lorenz1, F Weber2, H Dralle1,2.   

Abstract

BACKGROUND: A comprehensive assessment has not been undertaken of long-term outcomes in children carrying germline RET mutations and undergoing prophylactic thyroidectomy with the aim of preventing medullary thyroid cancer (MTC).
METHODS: A retrospective outcome study (1994-2017) of prophylactic thyroidectomy in children, with and without central node dissection, was performed at a tertiary surgical centre.
RESULTS: Some 167 children underwent prophylactic thyroidectomy, 109 without and 58 with concomitant central node dissection. In the highest-risk mutational category, MTC was found in five of six children (83 per cent) aged 3 years or less. In the high-risk category, MTC was present in six of 20 children (30 per cent) aged 3 years or less, 16 of 36 (44 per cent) aged 4-6 years, and 11 of 16 (69 per cent) aged 7-12 years (P = 0·081). In the moderate-risk category, MTC was seen in one of nine children (11 per cent) aged 3 years or less, one of 26 (4 per cent) aged 4-6 years, three of 26 (12 per cent) aged 7-12 years, and seven of 16 (44 per cent) aged 13-18 years (P = 0·006). Postoperative hypoparathyroidism was more frequent in older children (32 per cent in the oldest age group versus 3 per cent in the youngest; P = 0·002), whether or not central node dissection was carried out. Three children developed recurrent laryngeal nerve palsy; all had undergone central node dissection (P = 0·040). All complications resolved within 6 months. Postoperative normalization of calcitonin serum levels was achieved in 114 (99·1 per cent) of 115 children with raised preoperative values. No residual structural disease or recurrence was observed.
CONCLUSION: Early prophylactic thyroidectomy is a viable surgical concept in experienced hands, sparing older children the postoperative morbidity associated with delayed neck surgery.
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29341155     DOI: 10.1002/bjs.10746

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  The RET C611Y mutation causes MEN 2A and associated cutaneous lichen amyloidosis.

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Lie Cao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-07-26       Impact factor: 3.335

Review 2.  MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Authors:  Vincent Amodru; David Taieb; Carole Guerin; Pauline Romanet; Nunzia Paladino; Thierry Brue; Thomas Cuny; Anne Barlier; Frederic Sebag; Frederic Castinetti
Journal:  Endocrine       Date:  2020-05-10       Impact factor: 3.633

Review 3.  5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine.

Authors:  Shu-Yuan Li; Yi-Qiang Ding; You-Liang Si; Mu-Jin Ye; Chen-Ming Xu; Xiao-Ping Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

4.  The RET C611Y mutation causes MEN 2A and associated cutaneous

Authors:  Xiao-Ping Qi; Jian-Zhong Peng; Xiao-Wei Yang; Zhi-Li Zao; Xiu-Hua Yu; Xu-Dong Fang; Da-Hong Zhang; Jian-Qiang Zhao
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

Review 5.  Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  J Endocr Soc       Date:  2018-07-13

6.  Preimplantation Genetic Testing of Multiple Endocrine Neoplasia Type 2A.

Authors:  Anders Würgler Hansen; Laura Kirstine Sønderberg Roos; Kristine Løssl; Christian Godballe; Jes Sloth Mathiesen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-14       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.